MYCOGRAFT 180MG TABLET

Mycograft 180 mg tablet is an anti-inflammatory medication with an active ingredient known as Mycophenolate sodium. It is part of the inosine-monophosphate dehydrogenase (IMPDH) inhibitor class. The medicine is prescribed to avoid rejection of organs in patients who have received the organs of a donor (such as heart, kidney transplantation, or liver). It is usually prescribed as a part of a combination treatment, including other immunosuppressive medicines.
This medication is not recommended during pregnancy due to the possibility of miscarriage and congenital disabilities. It is not recommended for pregnant women unless there are no other suitable alternatives and the possible advantages outweigh the risks. Women who are prone to conceive are strongly advised to utilize the most effective contraception when taking this tablet to avoid the possibility of pregnancy. Live vaccines shouldn’t be administered while a patient takes the Mycograft 180 mg tablet due to the decreased effectiveness of the vaccine and increased risk of contracting an infection. Patients taking this medication must not give blood during treatment and, at minimum, six weeks after having stopped treatment. This ensures that the drug is eliminated from the body before blood donation.
It is usually advised not to take this drug in case you have an allergy to the medication or other ingredients. Inform your physician if you suffer from heart or liver disease before starting the treatment. Because this medication reduces the body’s immune defenses, it increases the risk of developing skin cancer. People should minimize exposure to sunlight and UV (UV) radiation. Contact your doctor immediately when you experience surface swelling, fever, or other unidentified fatigue, dizziness, eyes, or skin. Eyes or eyes, vision impairment, decreased urine output, or seizures after taking this medication. Mycograft 180 mg tablet is an immunosuppressive drug. It can affect a baby’s growing immune system and must be avoided while breastfeeding.